Woon-Kai Low

Title: Woon-Kai Low: Innovator in Anticancer Research

Introduction

Woon-Kai Low is a notable inventor based in Baltimore, MD, who has made significant contributions to the field of immunosuppressive agents and anticancer research. With a total of two patents to his name, his work focuses on developing novel compounds that target cancer cells while minimizing toxicity to normal cells.

Latest Patents

Woon-Kai Low's latest patents include compositions related to potent immunosuppressive agents and anticancer agents. These patents describe simplified analogs of pateamine A, which are devoid of the C3-amino and C5-methyl groups. The analogs exhibit anticancer and antiproliferative effects both in vivo and in vitro by inhibiting eIF4A-dependent translation initiation. They are designed to cause cell cycle arrest or induce apoptosis in transformed cells while maintaining low toxicity to slow-growing normal cells. Furthermore, these analogs serve as valuable molecular probes for evaluating eukaryotic translation initiation and as lead compounds for developing improved anticancer agents.

Career Highlights

Woon-Kai Low has worked with prestigious institutions such as the Texas A&M University System and Johns Hopkins University. His research has focused on the mechanisms of action of novel drugs and their potential applications in cancer treatment.

Collaborations

Some of Woon-Kai Low's notable coworkers include Daniel Romo and Jun O Liu, who have contributed to his research endeavors and advancements in the field.

Conclusion

Woon-Kai Low's innovative work in the development of anticancer agents and immunosuppressive compounds highlights his significant impact on medical research. His contributions continue to pave the way for advancements in cancer treatment and therapeutic applications.